**media[1139120]**First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof.Patient care and research delivered in collaboration with the Melbourne Theranostic Innovation Centre (MTIC), led by its world-class clinical research team.MELBOURNE, Australia, July 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today officially opens a multi-million dollar radiopharmaceutical research, manufacturing and treatment facility in Melbourne, expanding and strengthening Australia's capability in one of the world's fastest-growing areas of cancer diagnosis and treatment. Telix Manufacturing Solutions North Melbourne (TMSNM) is a purpose-built site that combines radiochemistry laboratories, clinical product manufacturing, patient dose administration and imaging. It is a first-of-its-kind Australian facility that integrates these capabilities at a single location. The facility will help address manufacturing capacity constraints and the need to make and administer radiopharmaceutical doses in close proximity to patients. It will link research, clinical trials and treatment, and is intended to significantly reduce the timeframe from early-stage trials to broad patient access.